Valproic acid

From Glioblastoma Treatments
Revision as of 08:53, 27 March 2024 by Lazy (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search
Property Information
Drug Name Valproic Acid/Sodium Valproate (Depakote)
FDA Approval Yes (for epilepsy)
Used for Investigational use in glioblastoma for its HDAC inhibition properties
Clinical Trial Phase Retrospective studies and a prospective phase II trial
Clinical Trial Explanation Not specified
Common Side Effects Liver enzyme non-induction, potential increase in chemotherapy concentration, somnolence, constipation, potential liver toxicity
OS without Median survival with enzyme-inducing anticonvulsants: 11 months
OS with Valproic acid users: retrospective study shows median survival of 16.9 months, prospective study shows 29.6 months
PFS without Not specified
PFS with Prospective study shows median PFS of 10.5 months
Usefulness Rating 3
Usefulness Explanation Not specified
Toxicity Level 3
Toxicity Explanation Valproic Acid/Sodium Valproate (Depakote) is a drug that has been used for epilepsy and is being investigated for the treatment of glioblastoma. It has risks associated with use, including potential liver toxicity, changes in levels of liver enzymes, increased concentration of chemotherapy in the body, plus side effects like sleepiness and constipation. These side effects and risks, while significant, are not the most severe among cancer treatments, thus rating it a 3 out of 5 for toxicity level.

Notes: Valproic acid, an anti-epileptic drug and HDAC inhibitor, has shown potential to improve clinical outcomes in glioblastoma patients. While initial retrospective analyses suggest benefits, particularly in extending median survival and PFS, the results are contested. The debate continues, emphasizing the need for rigorously designed clinical trials to conclusively determine Valproic acid's efficacy in glioblastoma treatment.


From Ben Williams Book: Not specified

Loading comments...